HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HNGE
Hinge Health, Inc.
HNGE lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HNGE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Strong | |
| Strong |
HNGE's revenue, cash flow and balance sheet are currently strong, and its profitability is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HNGE PE Valuation
HNGE has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HNGE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
HNGE has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over HNGE in the latest year-over-year earnings comparison.
HNGE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.92 | — |
| Q3 2025 | -$11.22 | -$10.43 |
| Q2 2025 | -$11.20 | -$10.20 |
| Q1 2025 | $1.76 | +$3.03 |
HNGE lost $11.22 per share over the past year, a bigger loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HNGE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $235M | +52% |
| Q2 2026 | $212.8M | +53% |
| Q1 2026 | $182.3M | +47% |
| Q4 2025 | $170.7M | +46% |
| Q3 2025 | $154.2M | +53% |
| Q2 2025 | $139.1M | +55% |
| Q1 2025 | $123.8M | +50% |
| Q4 2024 | $117.3M | +44% |
HNGE has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +25 points |
| Q2 2026 | 19% | +436 points |
| Q1 2026 | 18% | +7 points |
| Q4 2025 | 16% | -1.9 points |
| Q3 2025 | -4% | -0.1 points |
| Q2 2025 | -417% | -398 points |
| Q1 2025 | 11% | +49 points |
| Q4 2024 | 18% | +55 points |
HNGE has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
HNGE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $114.2M | +39% |
| Q1 2026 | $43M | +932% |
| Q4 2025 | $63.5M | +70% |
| Q3 2025 | $82.3M | +193% |
| Q1 2025 | $4.2M | +$37.8M |
HNGE has the edge over HIMS in the latest year-over-year cash flow comparison.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HNGE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HNGE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.7% | +3.1M shares |
| 1 year | +97% | +42.6M shares |
| 3 years | +11% | +8.5M shares |
HNGE has 87M diluted shares, up 97% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $25.9M |
| Q2 2026 | $26.5M |
| Q1 2026 | $105M |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HNGE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.4x | Net Cash |
| Q2 2026 | -2.9x | Net Cash |
| Q1 2025 | -15.7x | Net Cash |
HNGE has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HNGE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.7 | Overbought |
| Stochastic | 87.2 | Overbought |
HNGE's weekly RSI is 79 (overbought) and its Stochastic is 87 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HNGE PE vs Healthcare Sector
HNGE has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HNGE has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus HNGE above 3 of 3.
HNGE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $107.2 | 13% above |
| 20 week MA | $94.8 | 28% above |
| 50 week MA | $66.7 | 81% above |
HNGE is in an uptrend: it's above all three of its weekly moving averages, and 81% above its 50-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
HNGE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $40.2 | $47.5 | +18% |
| 2026 YTD | $47.5 | $121.0 | +155% |
HNGE has the edge over HIMS on returns for 2026, with the stronger performance.